07:59 AM EDT, 07/12/2024 (MT Newswires) -- Verastem ( VSTM ) said Friday the first patient had been dosed in a phase 1/2 trial conducted by GenFleet Therapeutics in China to assess investigational drug GFH375/VS-7375 in patients with advanced KRAS G12D mutant solid tumors.

The phase 1 study, which is underway in about 20 hospitals in China, will determine the recommended phase 2 dose, according to Verastem ( VSTM ). Phase 2 will evaluate the drug in patients with advanced solid tumors, such as pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer, the company added.

Verastem ( VSTM ) said it plans to initiate development studies outside of China after evaluating initial dose escalation data from the phase 1 study.

Price: 3.0000, Change: +0.02, Percent Change: +0.67